8.14
price up icon6.13%   0.47
after-market Handel nachbörslich: 8.09 -0.05 -0.61%
loading
Schlusskurs vom Vortag:
$7.67
Offen:
$7.61
24-Stunden-Volumen:
1.14M
Relative Volume:
0.81
Marktkapitalisierung:
$464.75M
Einnahmen:
$65,400
Nettoeinkommen (Verlust:
$-46.34M
KGV:
-8.8478
EPS:
-0.92
Netto-Cashflow:
$-38.74M
1W Leistung:
+14.17%
1M Leistung:
-25.39%
6M Leistung:
-27.32%
1J Leistung:
+54.17%
1-Tages-Spanne:
Value
$7.5671
$8.17
1-Wochen-Bereich:
Value
$7.05
$8.17
52-Wochen-Spanne:
Value
$3.61
$13.85

CorMedix Inc Stock (CRMD) Company Profile

Name
Firmenname
CorMedix Inc
Name
Telefon
908-517-9500
Name
Adresse
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Name
Mitarbeiter
14
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-25
Name
Neueste SEC-Einreichungen
Name
CRMD's Discussions on Twitter

Vergleichen Sie CRMD mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CRMD
CorMedix Inc
8.14 464.75M 65,400 -46.34M -38.74M -0.92
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

CorMedix Inc Stock (CRMD) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-07 Eingeleitet Leerink Partners Outperform
2025-01-13 Eingeleitet D. Boral Capital Buy
2024-08-26 Eingeleitet Rodman & Renshaw Buy
2023-08-10 Eingeleitet RBC Capital Mkts Outperform
2021-02-17 Eingeleitet Needham Buy
2020-09-29 Eingeleitet JMP Securities Mkt Outperform
2020-09-21 Eingeleitet Truist Buy
2019-12-18 Eingeleitet B. Riley FBR Buy
2019-03-26 Bestätigt H.C. Wainwright Buy
2018-12-06 Eingeleitet ROTH Capital Buy
2017-09-25 Bestätigt H.C. Wainwright Buy
2017-08-10 Bestätigt Rodman & Renshaw Buy
2017-05-05 Bestätigt Rodman & Renshaw Buy
2016-11-11 Bestätigt FBR & Co. Outperform
2016-03-17 Bestätigt FBR Capital Outperform
2016-03-03 Eingeleitet FBR Capital Outperform
2015-11-16 Bestätigt ROTH Capital Neutral
2015-10-29 Bestätigt ROTH Capital Neutral
2015-05-06 Herabstufung ROTH Capital Buy → Neutral
2014-12-08 Bestätigt ROTH Capital Buy
2011-10-03 Herabstufung Maxim Group Buy → Hold
Alle ansehen

CorMedix Inc Aktie (CRMD) Neueste Nachrichten

pulisher
Apr 17, 2025

Investors in CorMedix (NASDAQ:CRMD) have seen decent returns of 81% over the past five years - Yahoo Finance

Apr 17, 2025
pulisher
Apr 09, 2025

RBC stays bullish on CorMedix as Q1 preliminary revenue reassures on near-term - Yahoo Finance

Apr 09, 2025
pulisher
Apr 09, 2025

CorMedix expects Q1 sales above estimates, lifts H1 outlook - MSN

Apr 09, 2025
pulisher
Apr 08, 2025

CorMedix reports preliminary Q1 revenue $39M, consensus $32.2M. - TipRanks

Apr 08, 2025
pulisher
Apr 08, 2025

CorMedix at Needham Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada

Apr 08, 2025
pulisher
Apr 08, 2025

CorMedix at Needham Conference: Strategic Growth and Challenges - Investing.com

Apr 08, 2025
pulisher
Apr 08, 2025

CorMedix Stock Rises After Preliminary Q1 Results Exceeds Expectations: Retail’s Elated - MSN

Apr 08, 2025
pulisher
Apr 08, 2025

CRMD Soars 19.40% as CorMedix Announces Preliminary Q1 Results and Raises H1 Guidance, But Will the Momentum Continue? - RagingBull

Apr 08, 2025
pulisher
Apr 08, 2025

CorMedix Inc. Raises Financial Guidance for First Half of 2025 - MarketScreener

Apr 08, 2025
pulisher
Apr 08, 2025

CorMedix Sees Q1 Net Sales of $39 Million; Boosts H1 Net Sales Guidance - MarketScreener

Apr 08, 2025
pulisher
Apr 08, 2025

Cormedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance - The Manila Times

Apr 08, 2025
pulisher
Apr 08, 2025

CorMedix Logs Q1 Prel. Revenue Of $39 Mln - Nasdaq

Apr 08, 2025
pulisher
Apr 08, 2025

CorMedix reports strong preliminary Q1 revenue and EBITDA - Investing.com

Apr 08, 2025
pulisher
Apr 08, 2025

CorMedix Smashes Expectations: $39M Q1 Revenue and Massive Guidance Boost Signals Growth Acceleration - Stock Titan

Apr 08, 2025
pulisher
Apr 02, 2025

CorMedix Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times

Apr 02, 2025
pulisher
Apr 02, 2025

CorMedix CEO Sets Stage for Strategic Updates at Elite Needham Healthcare Conference - Stock Titan

Apr 02, 2025
pulisher
Mar 29, 2025

CorMedix Inc. (NASDAQ:CRMD) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 29, 2025
pulisher
Mar 28, 2025

CorMedix Inc. Reports Record Q4 Earnings and Growth - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

CorMedix: A Fair-Priced Biotech Company With A Bright Future - Seeking Alpha

Mar 28, 2025
pulisher
Mar 28, 2025

CORMEDIX ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire

Mar 28, 2025
pulisher
Mar 27, 2025

CORMEDIX ALERT: Bragar Eagel & Squire, P.C. is Investigating CorMedix Inc. on Behalf of ... - Bluefield Daily Telegraph

Mar 27, 2025
pulisher
Mar 27, 2025

Institutions along with individual investors who hold considerable shares inCorMedix Inc. (NASDAQ:CRMD) come under pressure; lose 35% of holdings value - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

CorMedix targets $50M-$60M revenue for H1 2025 with DefenCath growth - MSN

Mar 27, 2025
pulisher
Mar 27, 2025

CorMedix Inc.'s (NASDAQ:CRMD) 35% loss last week hit both individual investors who own 56% as well as institutions - simplywall.st

Mar 27, 2025
pulisher
Mar 26, 2025

Lost Money on CorMedix Inc.(CRMD)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire

Mar 26, 2025
pulisher
Mar 26, 2025

Kirby McInerney LLP Announces Investigation Against CorMedix Inc. (CRMD) on Behalf of Investors - GlobeNewswire

Mar 26, 2025
pulisher
Mar 26, 2025

The Hidden Risks Behind CorMedix's First Profitable Quarter (NASDAQ:CRMD) - Seeking Alpha

Mar 26, 2025
pulisher
Mar 26, 2025

CorMedix Inc (NASDAQ:CRMD) Order Delay - FXDailyReport.Com

Mar 26, 2025
pulisher
Mar 26, 2025

Long Term Trading Analysis for (CRMD) - news.stocktradersdaily.com

Mar 26, 2025
pulisher
Mar 26, 2025

INVESTOR ALERT: Investigation of CorMedix Inc. (CRMD) Announced by Holzer & Holzer, LLC - GlobeNewswire

Mar 26, 2025
pulisher
Mar 26, 2025

CorMedix Inc. (CRMD) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates - Louisiana First News

Mar 26, 2025
pulisher
Mar 26, 2025

Cormedix Inc (CRMD) Q4 2024 Earnings Call Highlights: A Profitable Quarter Amidst Strategic ... By GuruFocus - Investing.com Canada

Mar 26, 2025
pulisher
Mar 26, 2025

CorMedix Inc. Achieves Profitability with DefenCath Launch - TipRanks

Mar 26, 2025
pulisher
Mar 25, 2025

Rodman & Renshaw reiterates CorMedix stock Buy rating, $20 target By Investing.com - Investing.com Australia

Mar 25, 2025
pulisher
Mar 25, 2025

CorMedix: Q4 Earnings Snapshot - MySA

Mar 25, 2025
pulisher
Mar 25, 2025

Rodman & Renshaw reiterates CorMedix stock Buy rating, $20 target - Investing.com

Mar 25, 2025
pulisher
Mar 25, 2025

CorMedix (CRMD) Q4 2024 Earnings Call Transcript - AOL.com

Mar 25, 2025
pulisher
Mar 25, 2025

CorMedix earnings beat by $0.05, revenue topped estimates - Investing.com Canada

Mar 25, 2025
pulisher
Mar 25, 2025

Needham Cuts CorMedix's Price Target to $12 from $18, Keeps Buy Rating - MarketScreener

Mar 25, 2025
pulisher
Mar 25, 2025

CorMedix Stock Loses Almost A Third Of Its Market Cap After Downbeat H1 Revenue Outlook – But Retail Shrugs It - Asianet Newsable

Mar 25, 2025
pulisher
Mar 25, 2025

Cormedix: Positive Outlook with Strategic Advancements and Strong Financial Performance - TipRanks

Mar 25, 2025
pulisher
Mar 25, 2025

CorMedix Inc. (CRMD) Takes a Hit: What’s Behind the 31% Plunge? - RagingBull

Mar 25, 2025
pulisher
Mar 25, 2025

Nasdaq Gains 50 Points; US New Home Sales Rise In February - Benzinga

Mar 25, 2025
pulisher
Mar 25, 2025

CorMedix Stock Loses Almost A Third Of Its Market Cap After Downbeat H1 Revenue Outlook – But Retail Shrugs It Off - MSN

Mar 25, 2025
pulisher
Mar 25, 2025

Earnings call transcript: CorMedix Q4 2024 reports first profit, stock plunges - Investing.com Australia

Mar 25, 2025
pulisher
Mar 25, 2025

CorMedix shares tumble after order delay By Investing.com - Investing.com Philippines

Mar 25, 2025
pulisher
Mar 25, 2025

CorMedix shares tumble after order delay - Investing.com

Mar 25, 2025

Finanzdaten der CorMedix Inc-Aktie (CRMD)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
Kapitalisierung:     |  Volumen (24h):